| Attribute |
Value |
| 52 Week Change |
0.39766395 |
| Address1 |
777 Old Saw Mill River Road |
| All Time High |
1,211.2 |
| All Time Low |
3.0 |
| Ask |
837.25 |
| Ask Size |
1 |
| Audit Risk |
9 |
| Average Analyst Rating |
1.9 - Buy |
| Average Daily Volume10 Day |
640,900 |
| Average Daily Volume3 Month |
879,727 |
| Average Volume |
879,727 |
| Average Volume10Days |
640,900 |
| Beta |
0.188 |
| Bid |
807.83 |
| Bid Size |
2 |
| Board Risk |
10 |
| Book Value |
316.111 |
| City |
Tarrytown |
| Compensation As Of Epoch Date |
1,767,139,200 |
| Compensation Risk |
9 |
| Country |
United States |
| Crypto Tradeable |
0 |
| Currency |
USD |
| Current Price |
794.19 |
| Current Ratio |
3.335 |
| Custom Price Alert Confidence |
HIGH |
| Date Short Interest |
1,786,665,600 |
| Day High |
809.4 |
| Day Low |
789.075 |
| Debt To Equity |
8.535 |
| Display Name |
Regeneron Pharmaceuticals |
| Dividend Date |
1,788,134,400 |
| Dividend Rate |
3.76 |
| Dividend Yield |
0.47 |
| Earnings Call Timestamp End |
1,785,414,600 |
| Earnings Call Timestamp Start |
1,785,414,600 |
| Earnings Growth |
-0.045 |
| Earnings Quarterly Growth |
-0.068 |
| Earnings Timestamp |
1,785,414,600 |
| Earnings Timestamp End |
1,793,190,600 |
| Earnings Timestamp Start |
1,793,190,600 |
| Ebitda |
4,702,400,000 |
| Ebitda Margins |
0.3027 |
| Enterprise To Ebitda |
15.74 |
| Enterprise To Revenue |
4.765 |
| Enterprise Value |
74,015,834,112 |
| Eps Current Year |
53.54745 |
| Eps Forward |
60.61216 |
| Eps Trailing Twelve Months |
40.39 |
| Esg Populated |
0 |
| Ex Dividend Date |
1,787,011,200 |
| Exchange |
NMS |
| Exchange Data Delayed By |
0 |
| Exchange Timezone Name |
America/New_York |
| Exchange Timezone Short Name |
EDT |
| Fifty Day Average |
712.8952 |
| Fifty Day Average Change |
81.2948 |
| Fifty Day Average Change Percent |
0.11403471 |
| Fifty Two Week Change Percent |
39.766396 |
| Fifty Two Week High |
847.0 |
| Fifty Two Week High Change |
-52.809998 |
| Fifty Two Week High Change Percent |
-0.062349465 |
| Fifty Two Week Low |
541.0 |
| Fifty Two Week Low Change |
253.19 |
| Fifty Two Week Low Change Percent |
0.4680037 |
| Fifty Two Week Range |
541.0 - 847.0 |
| Financial Currency |
USD |
| First Trade Date Milliseconds |
670,602,600,000 |
| Float Shares |
95,787,894 |
| Forward Eps |
60.61216 |
| Forward P E |
13.102817 |
| Free Cashflow |
3,065,299,968 |
| Full Exchange Name |
NasdaqGS |
| Full Time Employees |
15,410 |
| Fullday Change |
-13.52 |
| Fullday Change Percent |
-1.67387 |
| Fullday Price |
793.2112 |
| Gmt Off Set Milliseconds |
-14,400,000 |
| Governance Epoch Date |
1,785,542,400 |
| Gross Margins |
0.44458 |
| Gross Profits |
6,906,399,744 |
| Has Pre Post Market Data |
1 |
| Held Percent Insiders |
0.02085 |
| Held Percent Institutions |
0.93496 |
| Implied Shares Outstanding |
102,954,988 |
| Industry |
Biotechnology |
| Industry Disp |
Biotechnology |
| Industry Key |
biotechnology |
| Ir Website |
http://newsroom.regeneron.com/ |
| Is Earnings Date Estimate |
1 |
| Language |
en-US |
| Last Dividend Date |
1,787,011,200 |
| Last Dividend Value |
0.94 |
| Last Fiscal Year End |
1,767,139,200 |
| Long Business Summary |
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. Additionally, the company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. It also has a strategic collaboration with CytomX Therapeutics, Inc. to create conditionally-activated bispecific cancer therapies. The company was incorporated in 1988 and is based in Tarrytown, New York. |
| Long Name |
Regeneron Pharmaceuticals, Inc. |
| Market |
us_market |
| Market Cap |
81,765,826,560 |
| Market State |
CLOSED |
| Max Age |
86,400 |
| Message Board Id |
finmb_33715 |
| Most Recent Quarter |
1,782,777,600 |
| Net Income To Common |
4,328,699,904 |
| Next Fiscal Year End |
1,798,675,200 |
| Non Diluted Market Cap |
83,157,773,356 |
| Number Of Analyst Opinions |
27 |
| Open |
809.4 |
| Operating Cashflow |
4,681,299,968 |
| Operating Margins |
0.33106 |
| Overall Risk |
10 |
| Payout Ratio |
0.090100005 |
| Peg Ratio |
1.38 |
| Phone |
914 847 7000 |
| Post Market Change |
-0.9788208 |
| Post Market Change Percent |
-0.12324768 |
| Post Market Price |
793.2112 |
| Post Market Time |
1,787,960,643 |
| Previous Close |
807.71 |
| Price Eps Current Year |
14.831518 |
| Price Hint |
2 |
| Price To Book |
2.512377 |
| Price To Sales Trailing12 Months |
5.2634315 |
| Profit Margins |
0.27865 |
| Quick Ratio |
2.633 |
| Quote Source Name |
Nasdaq Real Time Price |
| Quote Type |
EQUITY |
| Recommendation Key |
buy |
| Recommendation Mean |
1.89286 |
| Region |
US |
| Regular Market Change |
-13.52 |
| Regular Market Change Percent |
-1.67387 |
| Regular Market Day High |
809.4 |
| Regular Market Day Low |
789.075 |
| Regular Market Day Range |
789.075 - 809.4 |
| Regular Market Open |
809.4 |
| Regular Market Previous Close |
807.71 |
| Regular Market Price |
794.19 |
| Regular Market Time |
1,787,947,200 |
| Regular Market Volume |
487,713 |
| Return On Assets |
0.06526 |
| Return On Equity |
0.14043 |
| Revenue Growth |
0.167 |
| Revenue Per Share |
150.312 |
| Sand P52 Week Change |
0.1966995 |
| Sector |
Healthcare |
| Sector Disp |
Healthcare |
| Sector Key |
healthcare |
| Share Holder Rights Risk |
10 |
| Shares Outstanding |
101,137,842 |
| Shares Percent Shares Out |
0.0233 |
| Shares Short |
2,396,152 |
| Shares Short Previous Month Date |
1,784,073,600 |
| Shares Short Prior Month |
3,501,203 |
| Short Name |
Regeneron Pharmaceuticals, Inc. |
| Short Percent Of Float |
0.024600001 |
| Short Ratio |
3.0 |
| Source Interval |
15 |
| State |
NY |
| Symbol |
REGN |
| Target High Price |
1,030.0 |
| Target Low Price |
730.0 |
| Target Mean Price |
840.4285 |
| Target Median Price |
824.0 |
| Total Cash |
7,994,599,936 |
| Total Cash Per Share |
80.062 |
| Total Debt |
2,706,599,936 |
| Total Revenue |
15,534,699,520 |
| Tradeable |
0 |
| Trailing Annual Dividend Rate |
3.64 |
| Trailing Annual Dividend Yield |
0.004506568 |
| Trailing Eps |
40.39 |
| Trailing P E |
19.663036 |
| Trailing Peg Ratio |
1.3335 |
| Triggerable |
1 |
| Two Hundred Day Average |
727.9903 |
| Two Hundred Day Average Change |
66.19971 |
| Two Hundred Day Average Change Percent |
0.09093487 |
| Type Disp |
Equity |
| Volume |
487,713 |
| Website |
https://www.regeneron.com |
| Zip |
10,591-6707 |